As an indirect evidence, Wen et al. found that NRAS can be a target gene of miR-26a to improve the sensitivity of GC cells to cisplatin-based chemotherapies, which can be an evidence for the potential function of NRAS in chemotherapy for GC (Wen et al., 2015). This evidence concerns the gene NRAS and gastric cancer.